doi: 10.3969/j.issn.1674-9081.2019.05.008
  • Received Date: 2019-08-19
  • Publish Date: 2019-09-30
  • loading
  • [1] Martin L, Peche W, Peterson K, et al.Population Based Paternity Rate and Partner Birth Outcomes Among Utah Men With Inflammatory Bowel Disease[J]. Am J Gastroenterol, 2017, 112:1722-1727. doi:  10.1038/ajg.2017.279
    [2] Tavernier N, Fumery M, Peyrin-Biroulet L, et al.Systematic review:fertility in non-surgically treated inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2013, 38:847-853. doi:  10.1111/apt.12478
    [3] Mayberry JF, Weterman IT. European survey of fertility and pregnancy in women with Crohn's disease:a case control study by European collaborative group[J]. Gut, 1986, 27:821-825. doi:  10.1136/gut.27.7.821
    [4] Marri SR, Ahn C, Buchman AL. Voluntary childlessness is increased in women with inflammatory bowel disease[J]. Inflamm Bowel Dis, 2007, 13:591-599. doi:  10.1002/ibd.20082
    [5] Ording Olsen K, Juul S, Berndtsson I, et al. Ulcerative colitis:female fecundity before diagnosis, during disease, and after surgery compared with a population sample[J]. Gastroenterology, 2002, 122:15-19. doi:  10.1053/gast.2002.30345
    [6] Waljee A. Waljee J, Morris AM, et al. Threefold increased risk of infertility:a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis[J]. Gut, 2006, 55:1575-1580. doi:  10.1136/gut.2005.090316
    [7] Rajaratnam SG, Eglinton TW, Hider P, et al.Impact of ileal pouch-anal anastomosis on female fertility:meta-analysis and systematic review[J]. Int J Colorectal Dis, 2011, 26:1365-1374. doi:  10.1007/s00384-011-1274-9
    [8] Ananthakrishnan AN, Martin C, Kane S, et al. Paternal Disease Activity Is Associated With Difficulty in Conception Among Men With Inflammatory Bowel Diseases[J]. Clin Gastroenterol Hepatol, 2019, 17:203-204. doi:  10.1016/j.cgh.2018.04.001
    [9] Orholm M, Munkholm P, Langholz E, et al. Familial occurrence of inflammatory bowel disease[J]. N Engl J Med, 1991, 324:84-88. doi:  10.1056/NEJM199101103240203
    [10] Peeters M, Nevens H, Baert F, et al. Familial aggregation in Crohn's disease:increased age-adjusted risk and concordance in clinical characteristics[J]. Gastroenterology, 1996, 111:597-603. doi:  10.1053/gast.1996.v111.pm8780562
    [11] Jolving LR, Nielsen J, Beck-Nielsen SS, et al. The Association Between Maternal Chronic Inflammatory Bowel Disease and Long-term Health Outcomes in Children-A Nationwide Cohort Study[J]. Inflamm Bowel Dis, 2017, 23:1440-1446. doi:  10.1097/MIB.0000000000001146
    [12] Orholm M, Fonager K, Sorensen HT. Risk of ulcerative colitis and Crohn's disease among offspring of patients with chronic inflammatory bowel disease[J]. Am J Gastroenterol, 1999, 94:3236-3238. doi:  10.1111/j.1572-0241.1999.01526.x
    [13] Bennett RA, Rubin PH, Present DH. Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease[J]. Gastroenterology, 1991, 100:1638-1643. doi:  10.1016/0016-5085(91)90663-6
    [14] Laharie D, Debeugny S, Peeters M, et al.Inflammatory bowel disease in spouses and their offspring[J]. Gastroenterology, 2001, 120:816-819. doi:  10.1053/gast.2001.22574
    [15] Julsgaard M, Norgaard M, Hvas CL, et al.Self-reported adherence to medical treatment prior to and during pregnancy among women with ulcerative colitis[J]. Inflamm Bowel Dis, 2011, 17:1573-1580. doi:  10.1002/ibd.21522
    [16] Nielsen MJ, Norgaard M, Holland-Fisher P, et al.Self-reported antenatal adherence to medical treatment among pregnant women with Crohn's disease[J]. Aliment Pharmacol Ther, 2010, 32:49-58. doi:  10.1111/j.1365-2036.2010.04318.x
    [17] de Lima A, Zelinkova Z, Mulders AG, et al. Preconception Care Reduces Relapse of Inflammatory Bowel Disease During Pregnancy[J]. Clin Gastroenterol Hepatol, 2016, 14:1285-1292.e1. doi:  10.1016/j.cgh.2016.03.018
    [18] Mountifield R, Andrews JM, Bampton P.It is worth the effort:Patient knowledge of reproductive aspects of inflammatory bowel disease improves dramatically after a single group education session[J]. J Crohns Colitis, 2014, 8:796-801. doi:  10.1016/j.crohns.2013.12.019
    [19] Reddy D, Murphy SJ, Kane SV, et al.Relapses of inflammatory bowel disease during pregnancy:in-hospital management and birth outcomes[J]. Am J Gastroenterol, 2008, 103:1203-1209. doi:  10.1111/j.1572-0241.2007.01756.x
    [20] Pedersen N, Bortoli A, Duricova D, et al. The course of inflammatory bowel disease during pregnancy and postpartum:a prospective European ECCO-EpiCom Study of 209 pregnant women[J]. Aliment Pharmacol Ther, 2013, 38:501-512. doi:  10.1111/apt.12412
    [21] Miller JP.Inflammatory bowel disease in pregnancy:a review[J]. J R Soc Med, 1986, 79:221-225. doi:  10.1177/014107688607900410
    [22] Bengtson MB, Solberg IC, Aamodt G, et al. Relationships between inflammatory bowel disease and perinatal factors:both maternal and paternal disease are related to preterm birth of offspring[J]. Inflamm Bowel Dis, 2010, 16:847-855. doi:  10.1002/ibd.21120
    [23] Mahadevan U, Sandborn WJ, Li DK, et al. Pregnancy outcomes in women with inflammatory bowel disease:a large community-based study from Northern California[J]. Gastroenterology, 2007, 133:1106-1112. doi:  10.1053/j.gastro.2007.07.019
    [24] Naganuma M, Kunisaki R, Yoshimura N, et al. Conception and pregnancy outcome in women with inflammatory bowel disease:A multicentre study from Japan[J]. J Crohns Colitis, 2011, 5:317-323. doi:  10.1016/j.crohns.2011.02.003
    [25] Stephansson O, Larsson H, Pedersen L, et al. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden[J]. Inflamm Bowel Dis, 2011, 17:795-801. doi:  10.1002/ibd.21369
    [26] Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy[J]. Gut, 2007, 56:830-837. doi:  10.1136/gut.2006.108324
    [27] Lin HC, Chiu CC, Chen SF, et al. Ulcerative colitis and pregnancy outcomes in an Asian population[J]. Am J Gastroenterol, 2010, 105:387-394. doi:  10.1038/ajg.2009.562
    [28] Bortoli A, Pedersen N, Duricova D, et al. Pregnancy outcome in inflammatory bowel disease:prospective European case-control ECCO-EpiCom study, 2003-2006[J]. Aliment Pharmacol Ther, 2011, 34:724-734. doi:  10.1111/j.1365-2036.2011.04794.x
    [29] Ito A, Iizuka B, Omori T, et al.Relationship between the Clinical Course of Ulcerative Colitis during Pregnancy and the Outcomes of Pregnancy:A Retrospective Evaluation[J]. Intern Med, 2018, 57:159-164. doi:  10.2169/internalmedicine.8550-16
    [30] Ujihara M, Ando T, Ishiguro K, et al. Importance of appropriate pharmaceutical management in pregnant women with ulcerative colitis[J]. BMC Res Notes, 2013, 6:210. doi:  10.1186/1756-0500-6-210
    [31] Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospita-lized ulcerative colitis:the Toronto consensus[J]. Gastroenterology, 2015, 148:1035-1058.e3. doi:  10.1053/j.gastro.2015.03.001
    [32] Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases:a systematic review[J]. Gut, 2012, 61:1619-1635. doi:  10.1136/gutjnl-2012-302830
    [33] Hanan IM. Inflammatory bowel disease in the pregnant woman[J]. Compr Ther, 1998, 24:409-414.
    [34] Kelley KE, Hernandez-Diaz S, Chaplin EL, et al. Identification of phthalates in medications and dietary supplement formulations in the United States and Canada[J]. Environ Health Perspect, 2012, 120:379-384. doi:  10.1289/ehp.1103998
    [35] Hernandez-Diaz S, Su YC, Mitchell AA, et al.Medications as a potential source of exposure to phthalates among women of childbearing age[J]. Reprod Toxicol, 2013, 37:1-5. doi:  10.1016/j.reprotox.2013.01.001
    [36] Dalrymple JM, Stamp LK, O'Donnell JL, et al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis[J]. Arthritis Rheum, 2008, 58:3299-3308. doi:  10.1002/art.24034
    [37] Dara P, Slater LM, Armentrout SA.Successful pregnancy during chemotherapy for acute leukemia[J]. Cancer, 1981, 47:845-846. doi:  10.1002/1097-0142(19810301)47:5<845::AID-CNCR2820470504>3.0.CO;2-4
    [38] Kozlowski RD, Steinbrunner JV, MacKenzie AH, et al.Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease[J]. Am J Med, 1990, 88:589-592. doi:  10.1016/0002-9343(90)90522-F
    [39] Martinez Lopez JA, Loza E, Carmona L. Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding)[J]. Clin Exp Rheumatol, 2009, 27:678-684.
    [40] Hernandez-Diaz S, Werler MM, Walker AM, et al.Folic acid antagonists during pregnancy and the risk of birth defects[J]. N Engl J Med, 2000, 343:1608-1614. doi:  10.1056/NEJM200011303432204
    [41] Smithells RW, Newman CG. Recognition of thalidomide defects[J]. J Med Genet, 1992, 29:716-723. doi:  10.1136/jmg.29.10.716
    [42] Peng X, Zhi M, Wei M, et al. Thalidomide results in diminished ovarian reserve in reproductive age female IBD patients[J]. Medicine (Baltimore), 2017, 96:e6540. doi:  10.1097/MD.0000000000006540
    [43] O'Morain C, Smethurst P, Dore CJ, et al. Reversible male infertility due to sulphasalazine:studies in man and rat[J]. Gut, 1984, 25:1078-1784. doi:  10.1136/gut.25.10.1078
    [44] Mahadevan U, Terdiman JP, Aron J, et al. Infliximab and semen quality in men with inflammatory bowel disease[J]. Inflamm Bowel Dis, 2005, 11:395-399. doi:  10.1097/01.MIB.0000164023.10848.c4
    [45] Villiger PM, Caliezi G, Cottin V, et al. Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis[J]. Ann Rheum Dis, 2010, 69:1842-1844. doi:  10.1136/ard.2009.127423
    [46] Teruel C, Lopez-San Roman A, Bermejo F, et al. Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines[J]. Am J Gastroenterol, 2010, 105:2003-2008. doi:  10.1038/ajg.2010.138
    [47] Dejaco C, Mittermaier C, Reinisch W, et al. Azathioprine treatment and male fertility in inflammatory bowel disease[J]. Gastroenterology, 2001, 121:1048-1053. doi:  10.1053/gast.2001.28692
    [48] Norgard B, Czeizel AE, Rockenbauer M, et al. Population-based case control study of the safety of sulfasalazine use during pregnancy[J]. Aliment Pharmacol Ther, 2001, 15:483-486. doi:  10.1046/j.1365-2036.2001.00962.x
    [49] Rahimi R, Nikfar S, Rezaie A, et al. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs:a meta-analysis[J]. Reprod Toxicol, 2008, 25:271-275. doi:  10.1016/j.reprotox.2007.11.010
    [50] Norgard B, Fonager K, Pedersen L, et al.Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy:a Danish cohort study[J]. Gut, 2003, 52:243-237. doi:  10.1136/gut.52.2.243
    [51] Akbari M, Shah S, Velayos FS, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease[J]. Inflamm Bowel Dis, 2013, 19:15-22. doi:  10.1002/ibd.22948
    [52] Coelho J, Beaugerie L, Colombel JF, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines:cohort from the CESAME Study[J]. Gut, 2011, 60:198-203. doi:  10.1136/gut.2010.222893
    [53] Casanova MJ, Chaparro M, Domenech E, et al. Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease[J]. Am J Gastroenterol, 2013, 108:433-440. doi:  10.1038/ajg.2012.430
    [54] Langagergaard V, Pedersen L, Gislum M, et al. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy:A Danish nationwide cohort study[J]. Aliment Pharmacol Ther, 2007, 25:73-81.
    [55] Kanis SL, de Lima-Karagiannis A, de Boer NKH, et al. Use of Thiopurines During Conception and Pregnancy Is Not Associated With Adverse Pregnancy Outcomes or Health of Infants at One Year in a Prospective Study[J]. Clin Gastroenterol Hepatol, 2017, 15:1232-1241.e1. doi:  10.1016/j.cgh.2017.02.041
    [56] Kane SV, Acquah LA. Placental transport of immunoglobulins:a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy[J]. Am J Gastroenterol, 2009, 104:228-233. doi:  10.1038/ajg.2008.71
    [57] Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease[J]. Clin Gastroenterol Hepatol, 2013, 11:286-292, e24. doi:  10.1016/j.cgh.2012.11.011
    [58] Cheent K, Nolan J, Shariq S, et al. Case Report:Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease[J]. J Crohns Colitis, 2010, 4:603-605. doi:  10.1016/j.crohns.2010.05.001
    [59] Mahadevan U, Martin CF, Sandler RS, et al. PIANO:a 1000 patient prospective registry of pregnancy outcomes in women with ibd exposed to immunomodulators and biologic therapy[J]. Gastroenterology, 2012, 142:S149.
    [60] Julsgaard M, Kjeldsen J, Baumgart DC.Vedolizumab safety in pregnancy and newborn outcomes[J]. Gut, 2017, 66:1866-1867. doi:  10.1136/gutjnl-2016-313444
    [61] Mahadevan U, Vermeire S, Lasch K, et al. Vedolizumab exposure in pregnancy:outcomes from clinical studies in inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2017, 45:941-950. doi:  10.1111/apt.13960
    [62] Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids:prospective cohort study and meta-analysis of epidemiological studies[J]. Teratology, 2000, 62:385-392. doi:  10.1002/1096-9926(200012)62:6<385::AID-TERA5>3.0.CO;2-Z
    [63] Hviid A, Molgaard-Nielsen D.Corticosteroid use during pregnancy and risk of orofacial clefts[J]. Cmaj, 2011, 183:796-804. doi:  10.1503/cmaj.101063
    [64] Martel MJ, Rey E, Beauchesne MF, et al. Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension:nested case-control study[J]. BMJ, 2005, 330:230. doi:  10.1136/bmj.38313.624352.8F
    [65] Bar Oz B, Hackman R, Einarson T, et al.Pregnancy outcome after cyclosporine therapy during pregnancy:a meta-analysis[J]. Transplantation, 2001, 71:1051-1055. doi:  10.1097/00007890-200104270-00006
    [66] Branche J, Cortot A, Bourreille A, et al. Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy[J]. Inflamm Bowel Dis, 2009, 15:1044-1048. doi:  10.1002/ibd.20858
    [67] Piper JM, Mitchel EF, Ray WA.Prenatal use of metronidazole and birth defects:no association[J]. Obstet Gynecol, 1993, 82:348-352.
    [68] Koss CA, Baras DC, Lane SD, et al. Investigation of metronidazole use during pregnancy and adverse birth outcomes[J]. Antimicrob Agents Chemother, 2012, 56:4800-4805. doi:  10.1128/AAC.06477-11
    [69] Linseman DA, Hampton LA, Branstetter DG. Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin[J]. Fundam Appl Toxicol, 1995, 28:59-64. doi:  10.1006/faat.1995.1146
    [70] Bernstein CN, Blanchard JF, Houston DS, et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease:a population-based cohort study[J]. Thromb Haemost, 2001, 85:430-434. doi:  10.1055/s-0037-1615600
    [71] Pomp ER, Lenselink AM, Rosendaal FR, et al. Pregnancy, the postpartum period and prothrombotic defects:risk of venous thrombosis in the MEGA study[J]. J Thromb Haemost, 2008, 6:632-637. doi:  10.1111/j.1538-7836.2008.02921.x
    [72] 中华医学会消化病学分会炎症性肠病学组.中国住院炎症性肠病患者静脉血栓栓塞症防治的专家共识意见[J].中华炎性肠病杂志, 2018, 2:75-82.
    [73] Killeen S, Gunn J, Hartley J. Surgical management of complicated and medically refractory inflammatory bowel disease during pregnancy[J]. Colorectal Dis, 2017, 19:123-138. doi:  10.1111/codi.13413
    [74] Panes J, Bouzas R, Chaparro M, et al. Systematic review:the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease[J]. Aliment Pharmacol Ther, 2011, 34:125-145. doi:  10.1111/j.1365-2036.2011.04710.x
    [75] Schreyer AG, Menzel C, Friedrich C, et al. Comparison of high-resolution ultrasound and MR-enterography in patients with inflammatory bowel disease[J]. World J Gastroenterol, 2011, 17:1018-1025.
    [76] Stern MD, Kopylov U, Ben-Horin S, et al. Magnetic resonance enterography in pregnant women with Crohn's disease:case series and literature review[J]. BMC Gastroenterol, 2014, 14:146. doi:  10.1186/1471-230X-14-146
    [77] Birchard KR, Brown MA, Hyslop WB, et al. MRI of acute abdominal and pelvic pain in pregnant patients[J]. AJR Am J Roentgenol, 2005, 184:452-458. doi:  10.2214/ajr.184.2.01840452
    [78] Tremblay E, Therasse E, Thomassin-Naggara I, et al. Quality initiatives:guidelines for use of medical imaging during pregnancy and lactation[J]. Radiographics, 2012, 32:897-911. doi:  10.1148/rg.323115120
    [79] Schulze H, Esters P, A Dignass.Review article:the management of Crohn's disease and ulcerative colitis during pregnancy and lactation[J]. Aliment Pharmacol Ther, 2014, 40:991-1008. doi:  10.1111/apt.12949
    [80] Nguyen GC, Seow CH, Maxwell C, et al. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy[J]. Gastroenterology, 2016, 150:734-757.e1. doi:  10.1053/j.gastro.2015.12.003
    [81] van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease[J]. J Crohns Colitis, 2015, 9:107-124. doi:  10.1093/ecco-jcc/jju006
    [82] Shergill AK, Ben-Menachem T, Chandrasekhara V, et al. Guidelines for endoscopy in pregnant and lactating women[J]. Gastrointest Endosc, 2012, 76:18-24. doi:  10.1016/j.gie.2012.02.029
    [83] Ludvigsson JF, Lebwohl B, Ekbom A, et al. Outcomes of Pregnancies for Women Undergoing Endoscopy While They Were Pregnant:A Nationwide Cohort Study[J]. Gastroenterology, 2017, 152:554-563.e9. doi:  10.1053/j.gastro.2016.10.016
    [84] De Lima A, Galjart B, Wisse PH, et al. Does lower gastrointestinal endoscopy during pregnancy pose a risk for mother and child?-a systematic review[J]. BMC Gastroenterol, 2015, 15:15. doi:  10.1186/s12876-015-0244-z
    [85] Abdul Sultan A, West J, Ban L, et al. Adverse Pregnancy Outcomes Among Women with Inflammatory Bowel Disease:A Population-Based Study from England[J]. Inflamm Bowel Dis, 2016, 22:1621-1630. doi:  10.1097/MIB.0000000000000802
    [86] Foulon A, Dupas JL, Sabbagh C, et al. Defining the Most Appropriate Delivery Mode in Women with Inflammatory Bowel Disease:A Systematic Review[J]. Inflamm Bowel Dis, 2017, 23:712-720. doi:  10.1097/MIB.0000000000001112
    [87] Ananthakrishnan AN, Cheng A, Cagan A, et al. Mode of childbirth and long-term outcomes in women with inflammatory bowel diseases[J]. Dig Dis Sci, 2015, 60:471-477. doi:  10.1007/s10620-014-3353-6
    [88] Grouin A, Brochard C, Siproudhis L, et al. Perianal Crohn's disease results in fewer pregnancies but is not exacerbated by vaginal delivery[J]. Dig Liver Dis, 2015, 47:1021-1026. doi:  10.1016/j.dld.2015.08.001
    [89] McConnell RA, Mahadevan U.Pregnancy and the Patient with Inflammatory Bowel Disease:Fertility, Treatment, Delivery, and Complications[J]. Gastroenterol Clin North Am, 2016, 45:285-301. doi:  10.1016/j.gtc.2016.02.006
    [90] Burke KE, Haviland MJ, Hacker MR, et al. Indications for Mode of Delivery in Pregnant Women with Inflammatory Bowel Disease[J]. Inflamm Bowel Dis, 2017, 23:721-726. doi:  10.1097/MIB.0000000000001113
    [91] Smink M, Lotgering FK, Albers L, et al. Effect of childbirth on the course of Crohn's disease; results from a retrospective cohort study in the Netherlands[J]. BMC Gastroenterol, 2011, 11:6. doi:  10.1186/1471-230X-11-6
    [92] Bernstein CN, Banerjee A, Targownik LE, et al. Cesarean Section Delivery Is Not a Risk Factor for Development of Inflammatory Bowel Disease:A Population-based Analysis[J]. Clin Gastroenterol Hepatol, 2016, 14:50-57. doi:  10.1016/j.cgh.2015.08.005
    [93] Mahadevan U, McConnell RA, Chambers CD. Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease[J]. Gastroenterology, 2017, 152:451-462.e2. doi:  10.1053/j.gastro.2016.10.013
    [94] Branski D, Kerem E, Gross-Kieselstein E, et al. Bloody diarrhea-a possible complication of sulfasalazine transferred through human breast milk[J]. J Pediatr Gastroenterol Nutr, 1986, 5:316-317. doi:  10.1097/00005176-198605020-00028
    [95] Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease:Special situations[J]. J Crohns Colitis, 2010, 4:63-101. doi:  10.1016/j.crohns.2009.09.009
    [96] Ng SW, Mahadevan U. Management of inflammatory bowel disease in pregnancy[J]. Expert Rev Clin Immunol, 2013, 9:161-73; quiz 174.
    [97] Christensen LA, Dahlerup JF, Nielsen MJ, et al. Azathioprine treatment during lactation[J]. Aliment Pharmacol Ther, 2008, 28:1209-1213. doi:  10.1111/j.1365-2036.2008.03843.x
    [98] Sau A, Clarke S, Bass J, et al. Azathioprine and breastfeeding:is it safe?[J]. BJOG, 2007, 114:498-501. doi:  10.1111/j.1471-0528.2006.01232.x
    [99] Sammaritano LR, Bermas BL.Rheumatoid arthritis medications and lactation[J]. Curr Opin Rheumatol, 2014, 26:354-360. doi:  10.1097/BOR.0000000000000055
    [100] Moretti ME, Verjee Z, Ito S, et al. Breast-feeding during maternal use of azathioprine[J]. Ann Pharmacother, 2006, 40:2269-2272. doi:  10.1345/aph.1H152
    [101] Gotestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation[J]. Ann Rheum Dis, 2016, 75:795-810. doi:  10.1136/annrheumdis-2015-208840
    [102] Zelinkova Z, De Boer IP, Van Dijke MJ, et al. Azathioprine treatment during lactation[J]. Aliment Pharmacol Ther, 2009. 30: 90-91; author reply 91.
    [103] Nielsen OH, Maxwell C, Hendel J. IBD medications during pregnancy and lactation[J]. Nat Rev Gastroenterol Hepatol, 2014, 11:116-127. doi:  10.1038/nrgastro.2013.135
    [104] Niebyl JR.Antibiotics and other anti-infective agents in pregnancy and lactation[J]. Am J Perinatol, 2003, 20:405-414. doi:  10.1055/s-2003-45391
    [105] WHO. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans: Vol. 50 Pharmaceutical Drugs[M].Lyon: International Agency for Research on Cancer, 1990: 77-114.
    [106] Yamada T, Mogi M, Kage T, et al. Enhancement by cyclosporin A of metastasis from hamster cheek pouch carcinoma[J]. Arch Oral Biol, 1992, 37:593-596. doi:  10.1016/0003-9969(92)90143-V
    [107] Pistilli B, Bellettini G, Giovannetti E, et al. Chemo-therapy, targeted agents, antiemetics and growth-factors in human milk:how should we counsel cancer patients about breastfeeding?[J]. Cancer Treat Rev, 2013, 39:207-211. doi:  10.1016/j.ctrv.2012.10.002
    [108] Johns DG, Rutherford LD, Leighton PC, et al. Secretion of methotrexate into human milk[J]. Am J Obstet Gynecol, 1972, 112:978-980. doi:  10.1016/0002-9378(72)90824-1
    [109] Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregn-ancy and breast-feeding[J]. Inflamm Bowel Dis, 2010, 16:881-895. doi:  10.1002/ibd.21154
    [110] Morton A. Cyclosporine and lactation[J]. Nephrology (Carlton), 2011, 16:249.
    [111] Ben-Horin S, Yavzori M, Kopylov U, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease[J]. J Crohns Colitis, 2011, 5:555-558. doi:  10.1016/j.crohns.2011.05.006
    [112] Kattah MG, Milush JM, Burt T, et al. Anti-TNF and thiopurine therapy in pregnant IBD patients does not signi-ficantly alter a panel of B-cell and T-cell subsets in 1-year-old infants[J]. Clin Transl Gastroenterol, 2018, 9:143. doi:  10.1038/s41424-018-0018-3
    [113] Esteve-Sole A, Deya-Martinez A, Teixido I, et al. Immunological Changes in Blood of Newborns Exposed to Anti-TNF-alpha during Pregnancy[J]. Front Immunol, 2017, 8:1123. doi:  10.3389/fimmu.2017.01123
    [114] Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection[J]. Gastroenterology, 2016, 151:110-119. doi:  10.1053/j.gastro.2016.04.002
    [115] Wieringa JW, Driessen GJ, Van Der Woude CJ.Pregnant women with inflammatory bowel disease:the effects of biologicals on pregnancy, outcome of infants, and the developing immune system[J]. Expert Rev Gastroenterol Hepatol, 2018, 12:811-818. doi:  10.1080/17474124.2018.1496820
  • 加载中


    通讯作者: 陈斌,
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索


    Article Metrics

    Article views (322) PDF downloads(398) Cited by()
    Proportional views


    DownLoad:  Full-Size Img  PowerPoint